ONCT News and Press, Oncternal Therapeutics Inc. From 05/20/21

Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...

Latest data from study TK216-01 remain encouraging, are consistent with previous results, and are updated over data contained in ASCO Abstract #11500 released today Two patients who achieved a complete response (CR) remain with no evidence of disease, one for over 24 months and ...

Latest data from the CIRLL study to be presented at ASCO 2021 remain encouraging, demonstrate good, continued enrollment, are consistent with previous results and are updated over data contained in abstract #7556 released today Objective response rate (ORR) of 83% (15 of 18 eval...

Oncternal Therapeutics (ONCT) has named Salim Yazji as its new chief medical officer ("CMO").He replaces acting CMO Edwina Baskin-Bey.Yazji founded Elpida Therapeutics in January 2019 and co-founded Ajuta Therapeutics.Oncternal shares closed up 6.4% to $5.30. For further details s...

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of industry veteran Salim Yazji, M.D., as Chief Medical Officer. ...

Image source: The Motley Fool. Oncternal Therapeutics, Inc. (NASDAQ: ONCT) Q1 2021 Earnings Call May 06, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Oncternal Therapeutics, Inc. (ONCT) Q1 2021 Earnings Call Tran...

Oncternal Therapeutics, Inc. (ONCT) Q1 2021 Earnings Conference Call May 06, 2021, 05:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President & Chief Executive Officer Edwina Baskin-Bey - Acting Chief Medical Officer Conference Call Participants ...

Oncternal Therapeutics (ONCT): Q1 GAAP EPS of -$0.12 misses by $0.02.Revenue of $0.75M (+29.3% Y/Y) misses by $0.36M.As of March 31, 2021, we had $111.2 million in cash and cash equivalents. We believe these funds will be sufficient to fund our operations into 2023. As of March 31, 2021, we h...

Interim results of a Phase 1b trial of cirmtuzumab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer compare favorably to historical single-agent paclitaxel data (57% ORR vs. ~30% ORR historical single-agent paclitaxel) In a preclinical ...

SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non-executive employees. The awa...